Please assess the completion status of the following clinical trial:

Trial Title: Prazosin for ETOH or Cocaine Craving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Current DSM-IV diagnosis of alcohol dependence or cocaine dependence with no use in last 30 days~* Capacity to provide informed consent~* Actively enrolled in chemical dependency treatment at VA Puget Sound English fluency~Exclusion Criteria:~* Evidence of significant abuse of opiates, PCP, sedatives or anxiolytics~* Suicidal ideation~* DSM IV diagnosis of bipolar mood disorder, schizophrenia or schizoaffective disorder~* Significant acute or chronic medical illness, including unstable angina, recent myocardial infarction, history of congestive heart failure, preexisting hypotension (systolic \< 110), or orthostatic hypotension (systolic drop \> 20mmHg after two minutes standing or any drop with dizziness), insulin-dependent diabetes mellitus; chronic renal or hepatic failure, pancreatitis, gout, M ni re's disease, benign positional vertigo, narcolepsy~* Concomitant use of alpha-1 antagonists History of prazosin-sensitivity Women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the investigator to be effective~* Non-compliance with outpatient chemical dependency treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: OTHER): Placebo no active medication
- prazosin (Type: ACTIVE_COMPARATOR): Prazosin flexible dose titration up to 12 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).